BLRX•benzinga•
BioLineRx Announces Oral Presentation On Data From Phase 1 Clinical Trial Evaluating Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapies In Sickle Cell Disease At ASH 2024
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 5, 2024 by benzinga